Kidney Week

Abstract: TH-PO889

Hepcidin Is a Potential Predictor Marker for Anemia Progression in Patients on Hemodialysis

Session Information

• Anemia and Iron Metabolism
  October 24, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Anemia and Iron Metabolism

• 200 Anemia and Iron Metabolism

Authors

• Uchida, Hiroki, Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu, Oita, Japan

Hiroki Uchida, MD

• Kurimoto, Ryo, Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu, Oita, Japan

Ryo Kurimoto, MBBS

• Suzuki, Miho, Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu, Oita, Japan

Miho Suzuki, MD

• Kudo, Akiko, Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu, Oita, Japan

Akiko Kudo, MD

• Nakata, Takeshi, Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu, Oita, Japan

Takeshi Nakata, MD

• Fukuda, Akihiro, Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu, Oita, Japan

Akihiro Fukuda, MD, PhD

• Shibata, Hirotaka, Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu, Oita, Japan

Hirotaka Shibata, MD, PhD

Background

Higher hepcidin levels observed in patients on hemodialysis cause functional iron deficiency and erythropoiesis-stimulating agent hyporesponsiveness, which may result in anemia; however, the impact of hepcidin elevation on anemia in patients on hemodialysis remains unclear. This study assessed the association between hepcidin-25 and hemoglobin (Hb) levels in patients on hemodialysis.

Methods

This observational study included 44 outpatients on hemodialysis with 251 available blood test results between April and November 2023. Erythropoiesis-stimulating agents and hypoxia-inducible factor prolyl hydroxylase inhibitors were administered in 40 and 2 patients, respectively, whereas 2 patients did not receive anemia treatment. Transferrin saturation and Hb, ferritin, and serum hepcidin-25 levels were measured every month, and the association of same-month hepcidin-25 and Hb levels were assessed. Whether the hepcidin-25 levels predicted future anemia and changes in Hb levels was determined by assessing the associations of hepcidin-25 with the next-month Hb level and the changes in Hb level after 1 month.

Results

Hepcidin-25 levels, although not associated with the same-month Hb levels (ρ = −0.0377, P = 0.5528; Fig. 1), exhibited significant negative association with the next-month Hb levels (ρ = −0.2171, P = 0.0005; Fig. 1) and the changes in Hb levels (ρ = −0.1349, P = 0.0326; Fig. 2).Furthermore, Hb levels in the next month declined in patients with hepcidin-25 levels of >70 ng/mL (Fig. 3).

Conclusion

Our analyses demonstrated that hepcidin levels were useful in predicting anemia progression within a month in patients on hemodialysis. A hepcidin level of >70 ng/mL predicted anemia progression, suggesting the requirement for intensified anemia treatment in these patients on hemodialysis.